Lupin Tarapur API facility gets 3 observations from USFDA

The inspection of the Tarapur facility was carried out by the US health regulator between September 16 to September 20, 2019, said Lupin.

Mumbai: Pharma major Lupin Limited (Lupin) has received 3 observations from the United States Food and Drug Administration (U.S. FDA) for its Tarapur manufacturing (API) facility.

The inspection of the facility was carried out by the US health regulator between September 16 to September 20, 2019. USFDA issues three observations after inspecting the facility.

Commenting on the same, Lupin said, " The Company is confident of addressing them satisfactorily."

Read Also: Lupin gets USFDA nod for a generic equivalent of UNITHROID to treat thyroid

Based in Mumbai, Lupin is a player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAI D space and holds a global leadership position in the AntiTB segment.

Read Also: Lupin gets USFDA warning letter for Mandideep Unit-1 facility